GGrantIndex
← Leaderboards

Yi Lin

Mayo Clinic Rochester

$6,996,175
Attributed
$9,467,936
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201525
$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,467,936 · 6

By mechanism

R01$8,198,463 · 4
P50$737,688 · 1
K22$531,785 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsImmuneDendritic CellsMonocyteTumorImmunotherapyCytotoxicInnovationSignal TransductionT-LymphocyteResponseClinical TrialsMediatingImmune Checkpoint InhibitorAutologous Dendritic CellsPhenotypeCd14 GeneMorbidity - Disease RateLymphomaS LymphomaB-Cell Nonhodgkins LymphomaImmune FunctionImmunityCancer Type

Grant awards (23)

Radiation and dendritic cells to hepatomas to improve immunotherapy response$628,467
R01 · FY2025 · CA
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2025 · CA
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple Myeloma$280,796
P50 · FY2025 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,951
R01 · FY2024 · CA
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2024 · CA
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple Myeloma$266,018
P50 · FY2024 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,054
R01 · FY2023 · CA
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple Myeloma$190,874
P50 · FY2023 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$632,389
R01 · FY2022 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$485,760
R01 · FY2022 · CA · contact PI
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$713,488
R01 · FY2021 · CA · contact PI
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$401,153
R01 · FY2020 · CA · contact PI
Monocyte promotion of therapy resistance by immune and non-immune mechanisms$363,713
R01 · FY2020 · CA · contact PI
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$356,587
R01 · FY2019 · CA · contact PI
Monocyte promotion of therapy resistance by immune and non-immune mechanisms$352,801
R01 · FY2019 · CA · contact PI
Monocyte promotion of therapy resistance by immune and non-immune mechanisms$363,713
R01 · FY2018 · CA · contact PI
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$180,184
R01 · FY2018 · CA · contact PI
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma$545,997
R01 · FY2017 · CA · contact PI
Monocyte promotion of therapy resistance by immune and non-immune mechanisms$363,713
R01 · FY2017 · CA · contact PI
Lymphoma monocyte crosstalk: mechanisms of chemo-immunotherapy resistance$146,520
K22 · FY2017 · CA · contact PI
Monocyte promotion of therapy resistance by immune and non-immune mechanisms$363,713
R01 · FY2016 · CA · contact PI
Lymphoma monocyte crosstalk: mechanisms of chemo-immunotherapy resistance$192,780
K22 · FY2016 · CA · contact PI
Lymphoma monocyte crosstalk: mechanisms of chemo-immunotherapy resistance$192,485
K22 · FY2015 · CA · contact PI